Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Brain Metastases Protection: Strategies to prevent and manage CNS progression
Treatment Selection Impact: How CNS protection factors into first- and second-line treatment decisions
Antibody-Drug Conjugates: Emerging data on CNS activity of antibody-drug conjugates in EGFR-mutated disease
Notable Insights:
Dr Dietrich: Was “very positively surprised” that amivantamab showed brain protection, noting it “seemed to have related to patients that had treated and untreated brain metastases as well.” He identified brain metastases as “both psychologically and somatically associated with a decline in quality of life.”
Dr Piotrowska: Supported osimertinib continuation for patients with well-controlled CNS disease who develop systemic progression. She emphasized the importance of “surveillance brain imaging on these patients, even periodically, if they didn’t have CNS disease at initial diagnosis.”